CHF and arrhythmias:
Indications for BIDIL:
Heart failure (HF) in black patients, as adjunct to standard treatment, to improve survival, prolong time to hospitalization for HF, and improve patient-reported functional status.
Limitations of Use:
Not established in NYHA Class IV HF.
Initially 1 tab 3 times daily, may reduce to ½ tab 3 times daily if not tolerated; titrate as tolerated after 3–5 days. Max 2 tabs 3 times daily.
Allergy to organic nitrates. Concomitant PDE5 inhibitors (eg, avanafil, sildenafil, tadalafil, vardenafil), or riociguat.
Correct volume/salt depletion prior to initiation. Hypotension. Hypertrophic cardiomyopathy. Discontinue if syncope occurs. Give pyridoxine if peripheral neuritis occurs. Hepatic impairment. Elderly. Pregnancy (Cat.C). Nursing mothers.
Vasodilators (nitrate + direct-acting).
See Contraindications. Severe hypotension with PDE5 inhibitors or riociguat.
Headache (usually transient), dizziness, asthenia, nausea, vomiting, hypotension, sinusitis, tachycardia, paresthesia, amblyopia; SLE.